Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer
- PMID: 26673243
- PMCID: PMC4740191
- DOI: 10.1097/RLU.0000000000001098
Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer
Abstract
Purpose: Metabolic activity, as defined by F-FDG uptake on PET, is a prognostic marker for multiple malignancies; however, no study has examined the prognostic value of imaging with FDG PET in stage I and II pancreatic cancer. We examined the value of PET FDG uptake in early-stage pancreatic cancer patients.
Methods: We identified patients with early-stage pancreatic cancer (I-II) who had FDG PET scan performed as part of their preoperative evaluation. The patients were divided into either high or low FDG uptake according to the median primary tumor standard uptake value (SUVmax). Our primary end points were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier estimate was used for survival analysis. Pathologic data were compared using the Fisher exact and χ tests.
Results: One hundred five patients were identified: 51 patients with low FDG uptake and 54 patients with high FDG uptake. Eighty-five patients (81%) had PET avid tumors, whereas 20 (19%) patients did not. High FDG uptake correlated with pathologic stage (P = 0.012). Patients with low FDG uptake had significantly better median OS than patients with high FDG uptake (28 vs. 16 months; P = 0.036). Patients with low-FDG uptake had significantly longer median RFS than patients with high FDG uptake (14 vs. 12 months; P = 0.049).
Conclusions: Low FDG uptake in PET scans in patients with stage I and II pancreatic cancer correlates with improved OS and RFS. This supports the concept that glucose metabolic pathways are important in pancreatic cancer biology and that PET scan activity can be used as a prognostic biomarker after pancreatectomy.
Conflict of interest statement
Figures
Similar articles
-
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.J Nucl Med. 2014 Jun;55(6):898-904. doi: 10.2967/jnumed.113.131847. Epub 2014 Apr 7. J Nucl Med. 2014. PMID: 24711649
-
Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.J Gastroenterol Hepatol. 2013 Feb;28(2):255-61. doi: 10.1111/jgh.12068. J Gastroenterol Hepatol. 2013. PMID: 23278193
-
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19. Acad Radiol. 2013. PMID: 22999369
-
Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.Hell J Nucl Med. 2013 May-Aug;16(2):97-102. doi: 10.1967/s002449910084. Epub 2013 May 20. Hell J Nucl Med. 2013. PMID: 23687644 Review.
-
The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer.Semin Nucl Med. 2020 Sep;50(5):434-446. doi: 10.1053/j.semnuclmed.2020.04.002. Epub 2020 Jun 8. Semin Nucl Med. 2020. PMID: 32768007 Review.
Cited by
-
Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review.J Gastrointest Oncol. 2023 Apr 29;14(2):1114-1130. doi: 10.21037/jgo-22-1034. Epub 2023 Mar 29. J Gastrointest Oncol. 2023. PMID: 37201095 Free PMC article. Review.
-
Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?Int J Mol Sci. 2021 Jun 15;22(12):6413. doi: 10.3390/ijms22126413. Int J Mol Sci. 2021. PMID: 34203923 Free PMC article. Review.
-
Can Spectral Power Be Used as a Candidate Seizure Marker of the Periodic Discharges Pattern?Front Neurol. 2021 Jun 14;12:642669. doi: 10.3389/fneur.2021.642669. eCollection 2021. Front Neurol. 2021. PMID: 34194380 Free PMC article.
-
Venous thromboembolism detected by FDG-PET/CT in cancer patients: a common, yet life-threatening observation.Am J Nucl Med Mol Imaging. 2021 Apr 15;11(2):99-106. eCollection 2021. Am J Nucl Med Mol Imaging. 2021. PMID: 34079639 Free PMC article.
-
A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer.Front Oncol. 2021 May 12;11:650266. doi: 10.3389/fonc.2021.650266. eCollection 2021. Front Oncol. 2021. PMID: 34055620 Free PMC article.
References
-
- Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. - PubMed
-
- Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414–419. - PubMed
-
- Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: Insights from the past decade. Pharmacol Therap. 2013;137:318–330. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
